Kroeger N	FIS_60206
PI3K/AKT/mTOR pathway plays a major pathogenetic role in glycogen accumulation and tumor development in renal distal tubules of rats and men.
[Immunotherapy for advanced renal cell cancer].
Characterizing the impact of lymph node metastases on the survival outcome for metastatic renal cell carcinoma patients treated with targeted therapies.
Outcome of patients with metastatic sarcomatoid renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
One decade of improving palliative care of metastatic renal cell carcinoma by antiangiogenic therapies: time to move toward RCC cure.
[Pain therapy for acute renal colics: Nonsteroidal anti-inflammatory drugs (NSAIDs) and non-opioids].
Risk factors and model for predicting toxicity-related treatment discontinuation in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
Microvascular and lymphovascular tumour invasion are associated with poor prognosis and metastatic spread in renal cell carcinoma: a validation study in clinical practice.
Evaluation of the prognostic role of co-morbidities on disease outcome in renal cell carcinoma patients.
The VENUSS prognostic model to predict disease recurrence following surgery for non-metastatic papillary renal cell carcinoma: development and evaluation using the ASSURE prospective clinical trial cohort.
The cytosolic isoform of glutaredoxin 2 promotes cell migration and invasion
The cytosolic isoform of glutaredoxin 2 promotes cell migration and invasion